Effects of fenbendazole administration on hematology, clinical chemistries and selected hormones in the white Pekin duck.
The effects of single i.v. and p.o. doses (5 mg/kg) of fenbendazole, were evaluated on thyroxine, tri-iodothyronine, corticosterone, hematology, clinical chemistries, and serum proteins in 10 white Pekin ducks. Fenbendazole was administered i.v. (n = 5) as a 3% dimethyl sulfoxide solution and p.o. (n = 5) as a 10% commercial suspension. Serum enzyme concentrations, total protein and protein fractions, glucose, cholesterol, uric acid, sodium, and potassium were unchanged from baseline values. Serum triglycerides decreased consistently in the i.v.-treated group but remained unchanged in the p.o.-treated group. Serum chloride was consistently elevated above baseline values for both i.v.- and p.o.-treated ducks, while inorganic phosphate was consistently decreased only in the i.v.-treated group. Hemoglobin and hematocrit values generally were below baseline values. Leukocyte values varied considerably and were not significantly different from baseline values. Serum thyroxine and tri-iodothyronine values in both the i.v.- and p.o.-treated groups were not changed significantly from baseline values. Serum corticosterone values were not changed in the i.v.-treated groups but they were decreased at various times in the p.o.-treated group. Although there were some sporadic significant changes in the parameters measured versus baseline values all values remained within the physiologic limits for ducks. The safety of fenbendazole has been previously demonstrated for several species.
Pedersoli
W M
WM
Department of Physiology and Pharmacology, Auburn University, AL 36849.
Spano
J S
JS
Krista
L M
LM
Whitesides
J F
JF
Ravis
W R
WR
Kemppainen
R J
RJ
Young
D W
DW
D000284:Administration, Oral; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D001774:Blood Chemical Analysis / Q000662:veterinary; D001798:Blood Proteins / Q000032:analysis; D003345:Corticosterone / Q000097:blood; D004372:Ducks / Q000097:blood*; D004573:Electrolytes / Q000097:blood; D005273:Fenbendazole / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006400:Hematocrit / Q000662:veterinary; D007275:Injections, Intravenous; D008297:Male; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D001562:Benzimidazoles; D001798:Blood Proteins; D004573:Electrolytes; D014284:Triiodothyronine; D005273:Fenbendazole; D013974:Thyroxine; D003345:Corticosterone